Novo Nordisk Faces 16.3% Competitive Challenge, 16.4% Stock Drop from CagriSema Probe
Structure Therapeutics’ oral GLP-1 candidate aleniglipron achieved up to 16.3% placebo-adjusted weight loss at 44 weeks versus Wegovy’s 13.9% at 64 weeks, intensifying competitive pressure on Novo Nordisk. Meanwhile, a law firm probe into the Phase III failure of CagriSema, which dropped the stock 16.4%, heightens legal risk.
1. Oral GLP-1 Pill Matches Wegovy Efficacy
Structure Therapeutics’ ACCESS Phase II data showed aleniglipron delivered 16.3% placebo-adjusted weight loss at 44 weeks on the 180 mg dose and 16.2% at 56 weeks on the 120 mg dose, versus Wegovy’s 13.9% at 64 weeks. Trial discontinuations were under 4% compared with 6.9% for Wegovy, and no weight-loss plateau was observed, suggesting potential for extended efficacy.
2. CagriSema Phase III Failure and Stock Impact
Novo Nordisk’s experimental obesity drug CagriSema failed to meet non-inferiority against tirzepatide in its Phase III trial, triggering a 16.43% share price decline on February 23. The setback has led to a securities fraud investigation by the Portnoy Law Firm, adding legal risk to the investment case.
3. Valuation and Strategic Outlook
Despite recent setbacks and mounting competition, Novo Nordisk trades at a P/E of 10.42 with a dividend yield near 4.9% and free cash flow yield above 5.2%. The company is advancing its triple G agonist UBT251, entering a digital health partnership with Hims, and expanding its pipeline into MASH and heart failure to drive future growth.